Access to Radiation Therapy: From Local to Global and Equality to Equity.

The discipline of radiation oncology is the most resource-intensive component of comprehensive cancer care because of significant initial investments required for machines, the requirement of dedicated construction, a multifaceted workforce, and recurring maintenance costs. This review focuses on the challenges associated with accessible and affordable radiation therapy (RT) across the globe and the possible solutions to improve the current scenario. Most common cancers globally, including breast, prostate, head and neck, and cervical cancers, have a RT utilization rate of > 50%. The estimated annual incidence of cancer is 19,292,789 for 2020, with > 70% occurring in low-income countries and low-middle-income countries. There are approximately 14,000 teletherapy machines globally. However, the distribution of these machines is distinctly nonuniform, with low-income countries and low-middle-income countries having access to < 10% of the global teletherapy machines. The Directory of Radiotherapy Centres enlists 3,318 brachytherapy facilities. Most countries with a high incidence of cervical cancer have a deficit in brachytherapy facilities, although formal estimates for the same are not available. The deficit in simulators, radiation oncologists, and medical physicists is even more challenging to quantify; however, the inequitable distribution is indisputable. Measures to ensure equitable access to RT include identifying problems specific to region/country, adopting indigenous technology, encouraging public-private partnership, relaxing custom duties on RT equipment, global/cross-country collaboration, and quality human resources training. Innovative research focusing on the most prevalent cancers aiming to make RT utilization more cost-effective while maintaining efficacy will further bridge the gap.

Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective.

Surgery and radiotherapy, two locoregional cancer treatments, are essential to help improve cancer outcomes, control, and palliation. The continued evolution in treatment processes, techniques, and technologies-often at substantially increased costs-demands for direction on outcomes that are most valued by patients, and the evidence that is required before clinical adoption of these practices. Three recently introduced frameworks-the European Society for Medical Oncology Magnitude of Clinical Benefit Scale, the American Society of Clinical Oncology Value Framework, and the National Comprehensive Cancer Network Blocks-which all help define the value of oncology treatments, were appraised with a focus on their methods and definition of patient benefit. In this Review, we investigate the applicability of these frameworks to surgical and radiotherapy innovations. Findings show that these frameworks are not immediately transferable to locoregional cancer treatments. Moreover, the lack of emphasis on patient perspective and the reliance on traditional, trial-based endpoints such as survival, disease-free survival, and safety, calls for a new framework that includes real-world evidence with focus on the whole spectrum of patient-centred endpoints. Such an evidence-informed value scale would safeguard against the proliferation of low-value innovation while simultaneously increasing access to treatments that show significant improvements in the outcomes of cancer care.

Evaluation of image quality for different kV cone-beam CT acquisition and reconstruction methods in the head and neck region.

PURPOSE: To evaluate the image quality obtained in a standard QA phantom with both clinical and non-clinical cone-beam computed tomography (CBCT) acquisition modes for the head and neck (HN) region as a step towards CBCT-based treatment planning. The impact of deteriorated Hounsfield unit (HU) accuracy was investigated by comparing results from clinical CBCT image reconstructions to those obtained from a pre-clinical scatter correction algorithm. METHODS: Five different CBCT acquisition modes on a clinical system for kV CBCT-guided radiotherapy were investigated. Image reconstruction was performed in both standard clinical software and with an experimental reconstruction algorithm with improved beam hardening and scatter correction. Using the Catphan 504 phantom, quantitative measures of HU uniformity, HU verification and linearity, contrast-to-noise ratio (CNR), and spatial resolution using modulation transfer function (MTF) estimation were assessed. To benchmark the CBCT image properties, comparison to standard HN protocols on conventional CT scanners was performed by similar measures. RESULTS: The HU uniformity within a water-equivalent homogeneous region was considerably improved using experimental vs. standard reconstruction, by factors of two for partial scans and four for full scans. Similarly, the amount of capping/cupping artifact was reduced by more than 1.5%. With mode and reconstruction specific HU calibration using seven inhomogeneity inserts comparable HU linearity was observed. CNR was on average 5% higher for experimental reconstruction (scaled with the square-root of dose between modes for both reconstruction methods). CONCLUSIONS: Judged on parameters affecting the common diagnostic image properties, improved beam hardening and scatter correction diminishes the difference between CBCT and CT image quality considerably. In the pursuit of CBCT-based treatment adaptation, dedicated imaging protocols may be required.

A study of image-guided radiotherapy of bladder cancer based on lipiodol injection in the bladder wall.

PURPOSE: We have tested a procedure of focal injection of the contrast medium Lipiodol as a fiducial marker for image-guided boost of the tumor in bladder cancer radiotherapy (RT). In this study, we have evaluated the feasibility and the safety of the method as well as the inter- and intra-fraction shift of the bladder tumor. MATERIALS AND METHODS: Five patients with muscle invasive urinary bladder cancer were included in the study. Lipiodol was injected during flexible cystoscopy into the submucosa of the bladder wall at the periphery of the tumor or the post resection tumor-bed. Cone-beam CT (CBCT) scans were acquired daily throughout the course of RT. RESULTS: Lipiodol demarcation of the bladder tumor was feasible and safe with only a minimum of side effects related to the procedure. The Lipiodol spots were visible on CT and CBCT scans for the duration of the RT course. More than half of all the treatment fractions required a geometric shift of 5 mm or more to match on the Lipiodol spots. The mean intra-fraction shift (3D) of the tumor was 3 mm, largest in the anterior-posterior and cranial-caudal directions. CONCLUSION: This study demonstrates that Lipiodol can be injected into the bladder mucosa and subsequently visualized on CT and CBCT as a fiducial marker. The relatively large inter-fraction shifts in the positions of Lipiodol spots compared to the intra-fraction movement indicates that image-guided RT based on radio-opaque markers is important for RT of the bladder cancer tumor.

[Head and neck cancer patients' experiences with accelerated diagnostic and treatment programs]. / Hoved-hals-kraeft-patienters oplevelse af accelererede patientforløb.

INTRODUCTION: In 2007 Aarhus University Hospital succeeded in accelerating diagnostic and treatment programs for head and neck cancer patients. The median period from referral to initiation of treatment was reduced from 57 to 29 calendar days. This article reports the results of a qualitative study, which examined whether it was possible for patients to keep up with the program mentally as well as emotionally. MATERIAL AND METHODS: The study is based on semi-structured interviews with 20 head and neck cancer patients. RESULTS: The patients expressed great satisfaction with the accelerated programmes. Even though patients experienced the accelerated programs as very overwhelming, the vast majority did not at any time wish to postpone continuation of the programme. The study, however, shows that what is most important for the patient is fast treatment, good information and communication and good personal contact with the staff during the programme. CONCLUSION: Repetition of information and programme continuity is important as these factors allow patients to "keep up" with the programme. Personal contact and communication between patient and staff is essential for a successful accelerated programme. Time of diagnosis, scheduling of a date for the initial treatment or the start-up of the initial treatment are crucial turning points during the programme - points at which patients started feeling more calm.

[Accelerated diagnosis and treatment initiation for head and neck cancer patients]. / Accelererede udrednings- og behandlingsforløb for patienter med hoved-hals-kraeft.

INTRODUCTION: Acceleration of diagnosis and initiation of treatment for head and neck cancer requires optimal organisation and multidisciplinary collaboration. A project at the Head and Neck Oncology Centre, Aarhus University Hospital aimed at accelerating patient flow. MATERIALS AND METHODS: The initiatives were implemented throughout 2007. Focus was on optimizing logistics for all patients referred to the centre with suspected head and neck cancer. Initiatives included a full-time coordinator, pre-booked slots for clinical work-up and weekly tumour boards. Key dates were registered and relevant intervals were quantitatively evaluated and compared to a reference group from 2006. RESULTS: We registered 446 patients. Waiting times for first clinical examination at the ENT department were reduced from medially eight to two days through 2007 (p < 0.0001). Time from first clinical examination to referral for treatment was reduced from medially 21 to nine days (p < 0.0001). Time from referral to treatment to initiation of treatment was reduced from medially 26 to 15 days (p < 0,001). The net result of these reductions was a reduced overall median time (from primary referral to initiation of treatment) from medially 57 days by end of 2006 to medially 29 days by end of 2007 (p < 0,0001). CONCLUSION: Logistic changes and especially introduction of a full-time coordinator, a multidisciplinary tumour board and a generally higher priority for head and neck cancer patients resulted in a significant acceleration regarding diagnosis and start of treatment from 2006 to 2007.

Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies.

PURPOSE: Postmastectomy radiotherapy (RT) in high-risk breast cancer patients can reduce locoregional recurrences (LRRs) and improve disease-free and overall survival. The aim of this analysis was to examine the overall disease recurrence pattern among patients randomly assigned to receive treatment with or without RT. PATIENTS AND METHODS: A long-term follow-up was performed among the 3,083 patients from the Danish Breast Cancer Cooperative Group 82 b and c trials, except in those already recorded with distant metastases (DM) or contralateral breast cancer (CBC). The end points were LRR, DM, and CBC, and the follow-up continued until DM, CBC, emigration, or death. Information was selected from medical records, general practitioners, and the National Causes of Death Registry. The median potential follow-up time was 18 years. RESULTS: The 18-year probability of any first breast cancer event was 73% and 59% (P < .001) after no RT and RT, respectively (relative risk [RR], 0.68; 95% CI, 0.63 to 0.75). The 18-year probability of LRR (with or without DM) was 49% and 14% (P < .001) after no RT and RT, respectively (RR, 0.23; 95% CI, 0.19 to 0.27). The 18-year probability of DM subsequent to LRR was 35% and 6% (P < .001) after no RT and RT, respectively (RR, 0.15; 95% CI, 0.11 to 0.20), whereas the probability of any DM was 64% and 53% (P < .001) after no RT versus RT, respectively (RR, 0.78; 95% CI, 0.71 to 0.86). CONCLUSION: Postmastectomy RT changes the disease recurrence pattern in high-risk breast cancer patients; fewer patients have LRR as first site of recurrence, and overall fewer patients have DM.